A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.
CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role.
The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period.
The study will consist of two periods:
1. A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit.
2. A Treatment Period of 36 weeks.
On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded.
There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study.
The total study duration for a participant will be up to 40 weeks (approximately 9 months).

开始日期2025-06-30

申办/合作机构

Ipsen SA

IRCT20101012004920N11

/ Suspended临床3期

Comparison the efficacy and safety of botulinum toxin type A of Plasma Darman Sarve Sepid Company with Dysport® of Ipsen Co. in the treatment of the moderate to severe glabellar lines: a randomized, active controlled, double-blind, non-inferiority phase 3 trial

开始日期2025-04-21

申办/合作机构-

IRCT20200731048257N3

/ Recruiting临床1期

safety and effectiveness of Biosimilar Abobotulinum toxin type A in the treatment of moderate to severe frown lines, A phase I Clinical trials study

开始日期2024-10-31

申办/合作机构-

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的临床结果

登录后查看更多信息

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的转化医学

登录后查看更多信息

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的专利（医药）

登录后查看更多信息

1,127

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的文献（医药）

2025-07-01·CLINICAL NEUROLOGY AND NEUROSURGERY

The use of onabotulinum toxin type A and other neurotoxins for the treatment of chronic migraine: An American Headache Society survey study

Article

作者: Hamilton, Kendra ; Mathew, Paul G ; Ali, Ashhar ; Agarwal, Utkarsh

PURPOSE:

OnabotA is the only US Food and Drug Administration-approved neurotoxin for chronic migraine prevention; however, non-onabotA toxins may be equally effective. Few studies have explored clinician practices and patient outcomes with non-onabotA neurotoxins. Our study aimed to generate a statistical snapshot of clinician perspectives and treatment practices regarding onabotulinum toxin A (onabotA) and other neurotoxins for chronic migraine and comorbid conditions.

METHODS:

A 15-question survey was distributed online to clinician members of the American Headache Society (AHS) assessing clinical practices using onabotA and non-onabotA toxins for chronic migraine and comorbid conditions, and descriptive analysis was performed.

RESULTS:

168 respondents (162 from the United States and 6 from Canada) completed the survey (response rate 10.1 % [168/1665]). Of 48 respondents (28 % of total) using non-onabotA toxins for chronic migraine, 27 (16 %) used incobotulinum toxin A; 23 (14 %) used abobotulinum toxin A; and 12 (7 %) used rimabotulinum toxin B. Non-onabotA toxins were predominantly used due to administration/payor imposed issues (19/48; 40 %) and cost (18/48 [38 %]). Most clinicians using non-onabotA toxins reported similar efficacy to onabotA (32/48; 67 %), while fewer reported better efficacy (9/48 [19 %]) or worse efficacy (7/48 [15 %]) than onabotA. Many respondents (114/168 [68 %]) had used neurotoxins for chronic migraine in addition to other comorbid conditions, including temporomandibular joint disorders (95/114 [83 %]) and cervical dystonia (64/114 [56 %]).

CONCLUSION:

While non-onabotA toxins are used less frequently for chronic migraine, they may have similar efficacy as onabotA and are used off-label in clinical practice due to administrative/payor issues or cost.

2025-06-01·ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION

Longitudinal Goal Attainment With Repeat Injections of AbobotulinumtoxinA in Adults With Lower Limb Spasticity: Results From a Prospective Observational Study

Article

作者: Beneteau, Mathieu ; Ashford, Stephen ; Jacinto, Jorge ; Esquenazi, Alberto ; Hannes, Christian ; Maisonobe, Pascal ; Zorowitz, Richard D ; Zorowitz, Richard D.

OBJECTIVE:

To assess longitudinal goal attainment with repeat abobotulinumtoxinA (AboBoNT-A) injections for lower limb spasticity (LLS) over 16 months.

DESIGN:

Prospective, longitudinal, international, multicenter, observational study (NCT04050527).

SETTING:

Specialist neurorehabilitation centers.

PARTICIPANTS:

Ambulatory adults with unilateral LLS able to take ≥5 steps with/without assistance (effectiveness population, N=384).

INTERVENTIONS:

Participants received ≥1 AboBoNT-A treatment cycle administered in accordance with local prescribing guidelines to achieve individualized treatment goals.

MAIN OUTCOME MEASURES:

The primary endpoint was goal attainment as assessed using the cumulated Goal Attainment Scaling-Leg (GAS-leg) T score, across all treatment cycles for each patient.

RESULTS:

Overall, participants underwent a median of 5 lower limb injection cycles (median dose 600U, range 100-1475U) with a mean±SD injection interval of 18.3±6.1 weeks. Participants generally achieved their goals as expected over repeated cycles; the mean (95% CI) GAS-leg T score at cycle 1 baseline was 38.0 (37.7, 38.3) and the mean cumulated GAS-leg T score at 16 months was 48.2 (47.4, 48.9) (mean change from a baseline of 9.9 [9.1, 10.7]). Participants injected with a guidance technique at baseline were more likely to attain their cycle 1 primary treatment goals (odds ratio: 1.9 [95% CI 1.1, 3.1], P=.02). Overall, 56 (13.5%) participants reported ≥1 adverse event, of which 6 participants (1.4%) had a treatment-related adverse event.

CONCLUSIONS:

Findings from this large, international study provide evidence for the benefit of repeated cycles of AboBoNT-A for LLS. Multivariate analyses indicated that goal attainment during the first cycle was better with those injected using injection guidance than those injected without guidance.

2025-05-12·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Impact of botulinum therapy on long-term control of cervical dystonia symptoms and patient satisfaction with treatment: results of the international prospective observational study INTEREST IN CD2 in Russian subgroup of patients

Article

作者: Maisonobe, P. ; Pokhabov, D.B. ; Korenko, A.N. ; Khasanova, D.R. ; Karpova, M.I. ; Grigoryan, A.A. ; Baikova, A.N.

Objective. To evaluate effect of long-term BTA treatment on cervical dystonia (CD) symptoms control and patient satisfaction with botulinum therapy in real life setting. Material and methods. A total of 1050 patients took part in the international observational study INTEREST IN CD2, the analysis included data from 995 patients (overall population), of which 56 patients were enrolled In Russia. CD clinical assessment was performed at baseline and on the days of BTA injections using the TWSTRS scale and tremor component of the Tsui scale. Patient satisfaction with CD symptoms control was evaluated using 5-point Likert scale on the day of the visit (today satisfaction) and the highest level of satisfaction at any time since the last BTA injection (highest satisfaction). This article presents the results of the analysis of the Russian subgroup of patients in comparison with the overall study population. Results. In 5 Russian investigational sites, 44 (78.6%) women and 12 (21.4%) men were enrolled in the study; the patients’ mean age was 51.1±9.6 years, the mean duration of the disease was 7.3±5.6 years. The baseline characteristics of the Russian patients were comparable to the overall population, but severity of CD symptoms was numerically higher in the Russian subgroup: the mean TWSTRS severity scores were 17.4±5.0 and 15.9±5.7, respectively; segmental dystonia was observed more frequently (14.3% and 7.4% of patients), as well as shoulder elevation (73.2% and 50.5%) and jerk (21.4% and 9.6%). The vast majority of Russian patients (82.1%) received treatment with abobotulinumtoxin (Dysport). In the Russian subgroup, higher doses of Dysport (median doses 800.0 U and 500.0 U), larger number of targeted muscles (4.3±1.5 and 3.5±1.5) and injection points (11.7±5.5 and 8.1±5.0) were used compared to the overall population. In the Russian subgroup, the mean TWSTRS total score (assessed at the end of each injection cycle) decreased from 32.3±11.2 to 25.2±15.7 over the 3 years follow-up; there was also decrease in severity score from 17.4±5.0 to 12.6±7.5 and disability score from 9.8±4.0 to 7.4±4.8, comparable to the overall population. Patients’ satisfaction with CD symptoms control at peak of the BTA injection effect increased from 92.5% to 98.1% and was higher than in the overall population. At the end of the treatment cycle, patients’ satisfaction was consistently lower than at peak effect. Conclusion. The results of the Russian subgroup analysis showed a high level of long-term effectiveness of botulinum therapy in controlling CD symptoms and patients’ satisfaction with treatment in real clinical practice. Dysport is the most frequently used BTA preparation In Russia, the optimal level of effectiveness with repeated injections of Dysport remains stable and is maintained within the framework of real-life practice, which supports the clinical guidelines recommendations of its use as the drug of choice in the treatment of patients with CD.

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的新闻（医药）

2025-05-21

·药事纵横

23andMe 陨落，再生元 2.56 亿美元“抄底”

5月19日，生物制药巨头再生元（Regeneron Pharmaceuticals）宣布以2.56亿美元收购基因检测鼻祖23andMe，当日，23andMe股价盘前暴涨，而再生元股价则相对平稳。23andMe的故事始于2006年，创始人安妮·沃西基（Anne Wojcicki）凭借“唾液测基因”的创新模式，将消费级基因检测推向大众。通过祖源分析和健康风险评估，公司迅速积累1500万用户，市值一度飙升至60亿美元，成为硅谷明星企业。但这种商业模式的核心矛盾逐渐暴露：消费级基因检测并非刚需。用户多为一次性购买，复购率极低，而低价策略虽扩大了市场，却难以覆盖高昂的测序和数据处理成本，2024财年累计亏损23亿美元。 2023年的数据泄露事件，真正击垮了23andMe。黑客利用用户旧密码漏洞，窃取近700万客户的基因数据，包括家族关系、健康信息甚至出生年份。这不仅导致3000万美元的和解金，更让用户信任彻底崩塌。此后，公司裁员40%、关闭药物研发部门，最终于2025年3月申请破产保护，市值缩水至不足1亿美元。在这个节骨眼上，再生元瞄准了23andMe 1500万用户的基因数据库。再生元打的什么算盘？再生元以2.56亿美元“抄底”收购23andMe，要知道，23andMe巅峰时期估值60亿美元，如今仅以4%的价格收入囊中，且可选择性剥离亏损业务。近年来，再生元加速布局基因治疗，其VelociSuite平台依赖精准的基因靶点发现，而23andMe的海量数据能极大加速药物研发管线。此外，再生元此前收购的多家基因技术公司，如眼科递送技术公司Oxular、听力治疗公司Decibel均缺乏直接触达消费者的入口，23andMe的C端网络恰好填补这一空白。利用用户健康数据筛选临床试验受试者，或通过祖源分析定位特定疾病高发人群，实现个性化医疗的商业化落地。但是数据整合的难度不容小觑，消费级基因检测的数据质量与医学研究标准存在鸿沟：23andMe的祖源报告基于单核苷酸多态性（SNP）芯片，仅覆盖基因组中0.1%的位点，而药物研发需全基因组测序的深度数据。再生元能否将数据优化并准确应用，仍是未知数。尽管再生元承诺遵守隐私政策并接受法院监督，但毕竟有一次前车之鉴，可想而知公众对此仍然不够放心。23andMe的数据泄露阴影尚未消散，而基因数据的特殊性使其一旦泄露后果远超普通个人信息，因为它无法更改，且关联整个家族。况且，美国联邦法律对基因数据的保护极为有限：《健康保险可携性和责任法案》（HIPAA）仅适用于医疗机构，而《基因信息反歧视法》仅限制雇主和保险公司的歧视行为。即便加州等11个州赋予用户删除数据的权利，但再生元作为制药巨头，完全可能通过数据匿名化或研究合作绕过限制。伦理边界同样是一个难题，23andMe曾将匿名化数据授权给葛兰素史克（GSK）用于药物研发，用户虽签署同意书，但多数人并未意识到自己的基因可能成为药企的“原料”。再生元的收购加剧了这种疑虑：若数据用于开发天价罕见病药物，用户能否分享收益？若算法基于数据偏见导致医疗歧视，谁该负责？这些问题尚无明确答案，加州司法部长罗伯·邦塔（Rob Bonta）已发表紧急呼吁，要求用户立即删除数据。23andMe的失败暴露了消费级基因检测的商业化困局，但其数据的医疗价值仍不可否认，遗传病筛查、肿瘤基因检测、传染病诊断等更具刚需的领域成为新热点。再生元的收购或许预示着一种新模式：药企通过收购数据入口，直接打通研发与市场。早先，诺华、罗氏等巨头自建基因数据库；Ancestry、Color Health等公司则聚焦健康风险评估与临床结合。再生元的差异在于其试图将消费数据与药物开发深度绑定，例如利用人群基因多样性优化临床试验设计，或通过大数据预测药物副作用。若成功，这将彻底改变传统药企高投入、低产出的研发模式。但风险同样显著。23andMe的案例证明，数据驱动的商业模式极度依赖公众信任。再生元若无法解决隐私争议，可能重蹈覆辙。此外，消费基因检测与制药研发的文化差异也可能导致整合失败，前者追求用户增长与市场声量，后者注重科学严谨与合规性。对再生元而言，2.56亿美元的代价或许低廉，但如何将数据转化为真正的临床突破，如何平衡商业利益与用户权益，才是真正的试金石。参考来源：[1]Regeneron to Buy 23andMe for $256 Million in Bankruptcy Auction, by Haseeb Qureshi, Endpts, 2025-05-20[2]Pharmaceutical Company Regeneron Acquires Genetics Testing Firm 23andMe for $256 Million, by Benzinga, 2025-05-19[3]Regeneron to Acquire 23andMe for $256 Million, by Yahoo Finance, 2025-05-19药事纵横投稿须知：稿费已上调，欢迎投稿

并购基因疗法

2025-02-10

·PRNewswire

Connecticut Pain Solutions Offers Innovative Platelet-Rich Plasma (PRP) Treatments

WALLINGFORD, Conn., Feb. 10, 2025 /PRNewswire/ -- Connecticut Pain Solutions is excited to announce the availability of its cutting-edge Platelet-Rich Plasma (PRP) treatments. These advanced treatments are designed to address a range of conditions, offering patients a minimally invasive way to accelerate healing and improve their quality of life. Continue Reading Connecticut Pain Solutions is dedicated to providing exceptional care for those dealing with neurological conditions and chronic pain. The practice's mission is to combine state-of-the-art technology with compassionate, patient-centered care to deliver innovative solutions that improve lives. Our goal is always to stay ahead of the curve and provide our patients with the most cutting-edge solutions. Post this Led by Dr. Igor Turok, a board-certified and award-winning physician, the practice is at the forefront of advancements in neurological and pain treatments. Dr. Turok brings a wealth of knowledge and decades of experience, holding memberships in prestigious organizations such as the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Neurology and Psychiatry, the International Spine Intervention Society, and the American Society of Anesthesiologists. Dr. Turok has also earned recognition for his expertise in combining ultrasonography, electroencephalography, electromyography, and nystagmography in his treatment approaches. His innovative use of tools such as Magellan and Eclipse PRP® platelet-rich plasma centrifuges, Botox® and Dysport® for therapeutic purposes, and the Pro-Nox™ Nitrous Oxide System further emphasizes the practice's commitment to offering the most advanced care available. "We are thrilled to offer PRP therapy to our patients," said Dr. Igor Turok. "This innovative treatment opens up new possibilities for pain management and healing, using the body's natural abilities to restore and rejuvenate. Our goal is always to stay ahead of the curve and provide our patients with the most effective and cutting-edge solutions." Connecticut Pain Solutions offers the following services to address a wide range of needs and conditions: Advanced neurological diagnostics (EEG, EMG, and more) Pain management treatments (Botox®, PRP therapy, and more) Customized care for chronic conditions, including migraines and neuropathy Rehabilitation and recovery support About Connecticut Pain Solutions Connecticut Pain Solutions is a trusted name in neurological care and pain management, serving the Ridgefield and Wallingford communities. The practice takes pride in offering innovative treatments that prioritize patient well-being and long-term outcomes. Contact the team at Connecticut Pain Solutions to schedule an appointment or learn more about how PRP therapy and other treatments could improve lives. Wallingford Location: 101 N Plains Industrial Rd, Suite 100 Wallingford, CT 06492 Phone: (203) 626-9080 Ridgefield Location: 38B Grove St, Suite 203 Ridgefield, CT 06877 Phone: (475) 215-5660 Visit to learn more about the practice and its innovative offerings. SOURCE Connecticut Pain Solutions WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-23

·GlobeNewswire-Health Care

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024 YTD 2023 % change Q3 2024 Q3 2023 % change €m €m Actual CER1 €m €m Actual CER1 Oncology 1 829,8 1 744,1 4,9% 5,8% 604,0 574,5 5,1% 5,6% Neuroscience 536,4 489,0 9,7% 11,8% 181,9 164,8 10,4% 10,1% Rare Disease 129,7 76,0 70,7% 71,3% 50,8 33,2 53,1% 54,4% Total Sales 2 495,9 2 309,1 8,1% 9,2% 836,6 772,4 8,3% 8,6% Highlights Total-sales growth in the year to date of 9.2% at CER1, or 8.1% as reported, with notable performances from Dysport® (abobotulinumtoxinA), Cabometyx® (cabozantinib) and Bylvay® (odevixibat), with robust Somatuline® (lanreotide) sales, as well as the increasing contribution from the launches of Iqirvo® (elafibranor) in 2L PBC2 and Onivyde® (irinotecan) in 1L mPDAC3 Regulatory approvals in the E.U. of Iqirvo and Kayfanda® (odevixibat)Increased 2024 financial guidance: total-sales growth greater than 8.0% at CER1 (prior guidance: greater than 7.0% at CER1); core operating margin greater than 31.0% of total sales (prior guidance: greater than 30.0%) “Since the launch of our strategy in 2020, we have enjoyed uninterrupted growth. This quarter was no exception and was accompanied by further progress in the pipeline”, commented David Loew, Chief Executive Officer. “We have also continued to launch across several indications and lines of therapy, including the recent rollouts of Iqirvo and Onivyde, which are progressing well. Supported by the performance so far this year, we are further increasing our 2024 sales and margin guidance.” “We have built a track record of delivery, grounded in a strong foundation of external innovation, commercial excellence and our ongoing mission to offer more choices for patients.” Full-year 2024 guidance Based on the strong performance in the third quarter, Ipsen has further increased its financial guidance for 2024: Total-sales growth greater than 8.0%, at constant currency (prior guidance of greater than 7.0%). Based on the average level of exchange rates in September 2024, an adverse impact on total sales of around 1.5% from currencies is expectedCore operating margin greater than 31.0% of total sales (prior guidance of greater than 30.0%) Pipeline update In September 2024, the European Commission conditionally approved Iqirvo 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a monotherapy in patients unable to tolerate UDCA. Iqirvo was approved in the same setting by the U.S. FDA in June 2024. In September 2024, the European Commission also approved Kayfanda as a treatment for pruritus in children from as young as six months of age who have Alagille syndrome (ALGS). Odevixibat, under the brand name Bylvay, is already marketed in the E.U. for the treatment of progressive familial intrahepatic cholestasis (PFIC), and in the U.S. and E.U. for PFIC, and in the U.S. for ALGS. In the same month, final results from the CABINET Phase III trial were presented at the 2024 European Society for Medical Oncology Congress and were published in the New England Journal of Medicine, reinforcing the efficacy benefits of Cabometyx in advanced neuroendocrine tumors. It was announced at that time that Ipsen had submitted an extension of indication Marketing Authorization to the European Medicines Agency. Business development In August 2024, Ipsen entered into an agreement to sell its rare pediatric disease Priority Review Voucher. As part of the agreement, Ipsen received a cash payment of $158m in the third quarter. In October 2024, Eton Pharmaceuticals entered into an agreement with Ipsen to acquire Increlex® (mecasermin injection). The transaction is expected to close before the end of 2024. Arbitration proceedings with Galderma As of 30 September 2024, two arbitration proceedings initiated by Galderma against Ipsen at the International Chamber of Commerce (ICC) were ongoing. The first dispute, initiated by Galderma in 2021, pertains to the territorial scope of the commercial partnership related to Azzalure® (abobotulinumtoxinA) and Dysport under an agreement signed in 2007 in the E.U., in certain Eastern European countries, and in Central Asia. The Tribunal of the ICC Internal Court of Arbitration issued a final award, in October 2024, dismissing most, if not all, of Galderma's claims in this first arbitration and ordered that Galderma bear the majority of the legal fees and arbitration costs incurred by Ipsen. A second dispute was initiated by Galderma in November 2023, related to the validity of Ipsen’s 2023 termination of a joint R&D collaboration agreement entered into in 2014 under the parties’ respective early-stage neurotoxin programs, including the development of IPN10200. At this stage, Ipsen cannot reasonably predict any potential financial impact from this final remaining arbitration process, for which it intends to fully defend and vindicate its rights. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here. Calendar Ipsen intends to publish its full-year and fourth-quarter results on 13 February 2025. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2024 (YTD 2024) and the three-month period to 30 September 2024 (Q3 2024), compared to the nine-month period to 30 September 2023 (YTD 2023) and the three-month period to 30 September 2023 (Q3 2023), respectively. Commentary is based on the performance in YTD 2024, unless stated otherwise. About Ipsen Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fuelled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Ipsen contacts Investors Craig Marks +44 (0)7584 349 193 Nicolas Bogler +33 6 52 19 98 92 Media Jennifer Smith-Parker +44 (0) 7843 137 764Anne Liontas +33 7 67 34 72 96 1 At constant exchange rates (CER), which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.2 Second-line primary biliary cholangitis.3 First-line metastatic pancreatic ductal adenocarcinoma. Attachment Ipsen - YTD 2024 sales announcement

上市批准临床3期临床结果引进/卖出

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09764	A型肉毒杆菌毒素（Ipsen Biopharm Ltd）	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
面部皮肤病	中国	Ipsen Developments Ltd.	2020-06-17
肌肉痉挛	美国	Ipsen Biopharm Ltd.	2017-06-14
上下肢痉挛	美国	Ipsen Biopharm Ltd.	2016-07-29
眉间纹	美国	Ipsen Biopharm Ltd.	2009-04-29
斜颈	美国	Ipsen Biopharm Ltd.	2009-04-29
肌张力失调	奥地利	Ipsen SA	2009-01-28
肌张力失调	比利时	Ipsen SA	2009-01-28
肌张力失调	保加利亚	Ipsen SA	2009-01-28
肌张力失调	克罗地亚	Ipsen SA	2009-01-28
肌张力失调	塞浦路斯	Ipsen SA	2009-01-28
肌张力失调	捷克	Ipsen SA	2009-01-28
肌张力失调	丹麦	Ipsen SA	2009-01-28
肌张力失调	爱沙尼亚	Ipsen SA	2009-01-28
肌张力失调	芬兰	Ipsen SA	2009-01-28
肌张力失调	法国	Ipsen SA	2009-01-28
肌张力失调	德国	Ipsen SA	2009-01-28
肌张力失调	希腊	Ipsen SA	2009-01-28
肌张力失调	匈牙利	Ipsen SA	2009-01-28
肌张力失调	冰岛	Ipsen SA	2009-01-28
肌张力失调	爱尔兰	Ipsen SA	2009-01-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
偏头痛	临床3期	美国	Ipsen SA	2023-09-29
偏头痛	临床3期	加拿大	Ipsen SA	2023-09-29
偏头痛	临床3期	捷克	Ipsen SA	2023-09-29
偏头痛	临床3期	法国	Ipsen SA	2023-09-29
偏头痛	临床3期	格鲁吉亚	Ipsen SA	2023-09-29
偏头痛	临床3期	德国	Ipsen SA	2023-09-29
偏头痛	临床3期	波兰	Ipsen SA	2023-09-29
偏头痛	临床3期	西班牙	Ipsen SA	2023-09-29
下肢痉挛	临床3期	美国	Ipsen SA	2018-05-01
多发性硬化症	临床3期	美国	Ipsen SA	2016-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05167864 (JBDX, CTgov)	N/A	-	143	Onabotulinumtoxina for Injection (OnabotulinumtoxinA)	獵衊鏇壓繭願襯淵遞獵(艱壓壓鑰觸觸選淵夢顧) = 鑰蓋廠鹽襯選鏇網繭衊醖製艱廠選鑰醖襯廠艱 (網繭淵膚築鏇齋膚淵壓, 5.0) 更多	-	2025-01-17
				Abobotulinumtoxina for Injection (AbobotulinumtoxinA)	獵衊鏇壓繭願襯淵遞獵(艱壓壓鑰觸觸選淵夢顧) = 鬱構憲鏇憲簾艱繭醖積醖製艱廠選鑰醖襯廠艱 (網繭淵膚築鏇齋膚淵壓, 5.2) 更多
NCT05277337 (STAR, CTgov)	临床4期	眉间纹	150	Alluzience (Group 1 (Alluzience))	積積繭淵繭簾積蓋範夢(齋廠鹽蓋鏇艱夢觸願衊) = 鹽簾餘願觸醖鬱醖鹹鏇鏇蓋醖獵醖壓構選鬱齋 (顧簾艱夢憲範淵鏇鏇淵, 0.414) 更多	-	2024-02-16
				BoNT-A+Vistabel (Group 2 (Powder BoNT-A: BOTOX/Vistabel))	積積繭淵繭簾積蓋範夢(齋廠鹽蓋鏇艱夢觸願衊) = 廠鬱鹹選選選膚範憲願鏇蓋醖獵醖壓構選鬱齋 (顧簾艱夢憲範淵鏇鏇淵, 0.831) 更多
NCT03543254 (CTgov)	临床2期	偏头痛 \| 慢性病	20	BoNT-A	憲鏇築夢鹹鬱憲醖選繭 = 淵遞範積範壓蓋鏇積鬱構製築鹽糧糧網憲構選 (繭鑰選觸鹽鏇襯積積衊, 鏇獵糧獵遞簾糧蓋觸淵 ~ 齋構範構齋淵壓醖構獵) 更多	-	2024-01-30
MDS2022	N/A	颈肌张力障碍	27	Dysport	範獵鏇醖鑰遞醖襯餘淵(繭鹽艱鬱夢壓衊鹽簾顧) = 觸廠積願構觸鏇醖積構憲鏇齋網廠蓋遞窪網醖 (觸築願顧選觸襯鹹廠網 ) 更多	积极	2022-09-15
				Botox/Xeomin	餘壓憲醖繭襯憲觸憲窪(簾顧簾範繭糧齋築膚構) = 憲築構壓觸衊鬱壓醖願淵鑰壓襯窪鑰網廠餘積 (顧齋餘衊醖鹹選艱壓鑰 )
NCT03469999 (CTgov)	临床3期	脑瘫	12	Dysport	鬱網衊壓膚構襯願襯獵(膚觸夢醖鬱觸築醖醖餘) = 艱壓願鑰簾繭廠膚鬱窪鹹選醖襯淵網構網願夢 (艱鑰醖願壓鹽鏇繭繭網, 繭齋構製構觸夢鏇鑰鏇 ~ 齋廠繭鏇膚築遞糧獵餘) 更多	-	2022-06-01
NCT01459666 (CTgov)	临床4期	瘢痕 \| 额头皱纹 \| 皮肤肿瘤 ... 更多	9	Dysport (Dysport (abobotulinumtoxinA))	窪觸糧積醖繭艱蓋衊鹹(鏇積顧製顧遞淵艱壓襯) = 鹽廠蓋膚鹽選糧憲選糧積網獵糧襯艱範獵簾積 (範衊廠淵齋鏇製網襯憲, 窪願鹽顧遞淵膚獵鏇選 ~ 淵觸網繭構鹽齋積醖壓) 更多	-	2022-05-26
				Bacteriostatic 0.9% Sodium Chloride (vehicle) (Placebo)	窪觸糧積醖繭艱蓋衊鹹(鏇積顧製顧遞淵艱壓襯) = 願膚積齋網鑰選齋壓鏇積網獵糧襯艱範獵簾積 (範衊廠淵齋鏇製網襯憲, 製構鹽築齋壓鏇鏇構鏇 ~ 襯鹹選齋鑰簾壓憲壓鹹) 更多
NCT02660138 (CONTENT1, CTgov)	临床3期	尿失禁 \| 神经源性逼尿肌过度活动 \| 脊髓损伤 ... 更多	227	placebo (Placebo)	鏇築鹽選範艱鏇選鹹糧(觸構鏇鏇襯遞糧獵築積) = 醖鏇夢醖鬱壓餘鏇醖獵齋選繭鬱簾構製鏇鬱夢 (顧襯構構築淵廠繭膚獵, 2.01) 更多	-	2021-06-16
				Dysport (Dysport® 600 U)	鏇築鹽選範艱鏇選鹹糧(觸構鏇鏇襯遞糧獵築積) = 鹽齋繭築製範蓋鏇簾廠齋選繭鬱簾構製鏇鬱夢 (顧襯構構築淵廠繭膚獵, 2.04) 更多
AAN2021	N/A	颈肌张力障碍	-	AbobotulinumtoxinA 500U	觸鏇網糧獵網鏇構選獵(積醖窪憲糧艱顧構糧衊) = 遞襯製鏇顧餘鹽鑰衊鑰鏇齋鏇鏇製淵製醖夢積 (壓艱餘餘襯鹹廠獵窪鹽, 4.0)	-	2021-04-13
				Placebo	觸鏇網糧獵網鏇構選獵(積醖窪憲糧艱顧構糧衊) = 願淵醖積鬱衊鏇夢糧齋鏇齋鏇鏇製淵製醖夢積 (壓艱餘餘襯鹹廠獵窪鹽, 4.3)
NCT03736928 (CTgov)	临床2期	眉间纹	401	placebo	範襯鏇鑰觸窪繭淵觸壓 = 壓積範簾鬱範鏇襯簾願遞繭鬱鏇糧鑰築夢餘鬱 (繭壓憲選簾網蓋糧壓鬱, 範窪鹹齋襯願壓獵廠願 ~ 積膚蓋憲範壓壓製廠構) 更多	-	2021-02-11
NCT04080882 (CTgov)	临床2期	-	80	Placebo (Placebo)	餘鹽鹽願醖憲齋遞鬱艱 = 壓範蓋鹽鏇壓鏇簾鑰構醖艱鑰積廠壓夢製鑰夢 (糧構積築遞齋齋襯繭遞, 鬱構簾憲繭廠範艱鹹窪 ~ 製鬱築窪憲顧繭網糧壓) 更多	-	2021-01-22
				AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA Dose 1)	餘鹽鹽願醖憲齋遞鬱艱 = 鹹廠簾憲製蓋壓夢繭觸醖艱鑰積廠壓夢製鑰夢 (糧構積築遞齋齋襯繭遞, 鏇餘醖艱願艱壓艱構網 ~ 衊積鬱範鏇構獵憲廠築) 更多